New Up-to-Date Market Research Reports by FirstWord Recently Published at MarketPublishers.com13 Dec 2011 • by Natalie Aster
LONDON - Market Publishers Ltd informs that new up-to-date market research reports by FirstWord have been added to its catalogue.
Biosimilar Drugs in Europe: Threat or Opportunity to Innovation? In future a vast range of blockbuster drugs will go off patent, opening the floodgates in the EU to the biosimilars market. Already established there since 2006, biosimilars are set to be worth between $2.25 billion and $4.8 billion by 2015. The report examines the emerging biosimilars market. It analyses the market differences across Europe and different therapeutic areas. The impact of biosimilars on originator companies—and their response—is discussed, as well as strategies biosimilar companies. The study also offers insight into biosimilar deals and what the future holds in the EU …
Pharma Product Launches: Strategies for Success. Nowadays tight economic climate, shifting dynamics from prescribers to payers and increased generic competition have all meant that not only are there fewer pipeline drugs, there are fewer successful product launches. And those that do launch are not sufficient to contribute to market growth or even replace revenue from off-patent drugs. The study reviews information on how successful launch strategies can place pharmaceutical companies in a strong position, despite the weak market. It explains how and when to initiate launch planning and stakeholder engagement, the importance of creating pre-launch awareness and the importance of product differentiation …
More new market reports by the publisher can be found at FirstWord page.
The Market Publishers, Ltd.
Tel: +44 208 144 6009
Fax: +44 207 900 3970